Patients living with HIV infection are less likely to receive the correct statin intensity for cardiovascular disease risk reduction

Authors

Jason J. Schafer, PharmD, MPH, Thomas Jefferson UniversityFollow
Roshni Emmons, PharmD, BCPS, Thomas Jefferson UniversityFollow
Nick V. Hastain, PharmD, Thomas Jefferson UniversityFollow
Todd Miano, PharmD, PhD, The Hospital of the University of Pennsylvania

Files

Description

• Patients living with HIV (PLWH) are at high risk for atherosclerotic cardiovascular disease (ASCVD)
• Eligible PLWH should receive statins for ASCVD risk reduction according to current guidelines
• Studies suggest that statins are underprescribed in PLWH, but comparisons to uninfected patients and assessments of statin intensity have not occurred

Objective

To determine the influence of HIV infection on appropriate statin prescribing for ASCVD risk reduction

Publication Date

10-3-2019

Keywords

HIV, cardiovascular disease

Disciplines

Cardiology | Medicine and Health Sciences | Pharmacy and Pharmaceutical Sciences

Comments

Presented at ID Week

Recommended Citation

Schafer, PharmD, MPH, Jason J.; Emmons, PharmD, BCPS, Roshni; Hastain, PharmD, Nick V.; and Miano, PharmD, PhD, Todd, "Patients living with HIV infection are less likely to receive the correct statin intensity for cardiovascular disease risk reduction" (2019). College of Pharmacy Posters. 18.
https://jdc.jefferson.edu/pharmacyposters/18